BUSINESS INSIGHTS, PHARMACY MARKET

West Pharmaceutical Introduces Three New Product Innovations at Pharmapack Europe

West Pharmaceutical Services, Inc. | February 01, 2023 | Read time : 02:00 min

West Pharmaceutical

On January 31, 2023, West Pharmaceutical Services, Inc., a global pioneer in novel injectable drug administration solutions, announced its participation in Pharmapack Europe 2023 in Paris, France, to demonstrate its leadership and insights on industry packaging and containment trends and challenges.

With the introduction of three new products, the company expands its innovations for its patients and customers worldwide - Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System, West Ready Pack™ with Corning Valor® RTU Vials using Stevanato Group's EZ-fill® SG EZ-fill® technology and FluroTec® 5-10mL Cartridge Plunger.

West Pharmaceutical Services Vice President and General Manager, Biologics Li Chen commented, "This year, we are introducing three new product solutions at Pharmapack." He added, "With these innovations, we are addressing the growing market needs for today's complex and sensitive molecules, including large-volume delivery and a complete vial containment solution that can protect and scale from development through commercialization."

(Source – PR Newswire)

Meanwhile, West's participation in this year's conference includes the following

Learning Lab - How Market Trends Drive Innovation and Enable the Pharmaceutical Pipeline on Wednesday, February 1, 2023

Panel Session - Innovation of Novel Medicines and Trends in Demand for Injectable Home and Self-Administration on Wednesday, February 1, 2023

Innovation Tours - West Ready Pack™ with Corning Valor® RTU Vials using Stevanato Group's EZ-fill® Technology on Wednesday, February 1, 2023

Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System on Thursday, February 2, 2023

About West Pharmaceutical Services, Inc.

Founded in 1923, West Pharmaceutical Services, Inc. is a market leader in developing and delivering innovative, high-quality injectable solutions and services. As a trusted partner to both established and emergent drug producers, it contributes to the safe, effective containment and distribution of life-saving and life-enhancing medications to patients. West Pharmaceutical supports its clients by supplying over 45 billion components and devices annually, with roughly 10,000 team members spread across 50 facilities globally. The company marks its 100th anniversary of growth and innovation in 2023, as well as the essential role it continues to play in healthcare and the patient experience. Headquartered in Exton, Pennsylvania, it had generated $2.83 billion in net sales for the fiscal year 2021.

Spotlight

What’s next for the healthcare industry? Explore some of the groundbreaking developments that are leading to more individualized therapies and personalized medicine.

Spotlight

What’s next for the healthcare industry? Explore some of the groundbreaking developments that are leading to more individualized therapies and personalized medicine.

Related News

BUSINESS INSIGHTS, PHARMA TECH

Lyra Completes Enrollment in LYR-220 BEACON Phase 2 Clinical Trial

Lyra Therapeutics | February 08, 2023

On February 6, 2023, Lyra Therapeutics, Inc., a leading clinical-stage biotechnology firm developing novel therapies for the localized treatment of chronic rhinosinusitis (CRS), announced that enrollment in the Phase 2 BEACON clinical trial of LYR-220 in adult patients with CRS who have previously undergone sinus surgery has been completed. LYR-220 is designed to provide continuous anti-inflammatory medicine (mometasone furoate; MF) to the sinonasal passageways for six months in order to treat CRS. Topline outcomes are expected in the fourth quarter of 2023. The Phase 2 BEACON trial is a sham-controlled, parallel-group trial designed to assess the efficacy and safety of the LYR-220 (7500g MF) matrix in symptomatic adult CRS patients who have previously had bilateral ethmoid sinus surgery during a 24-week period. The trial is divided into two parts: Part 1 was aimed to examine the feasibility and tolerability of two 7500µg MF matrix designs; in Part 2, 40 patients were randomly assigned 1:1 to receive LYR-220 or sham control. Lyra revealed positive preliminary findings from the BEACON trial's Part 1, the non-randomized portion, in September 2022, indicating the feasibility and tolerability of bilateral LYR-220 placement in this patient population. In addition, all six patients were given the medication for at least six weeks, and no significant or unexpected side effects were recorded. Although efficacy evaluation was not the goal of the trial's uncontrolled Part 1 stage, there was a mean improvement of 21 points (37%) from baseline in the 22-item Sino-nasal Outcome Test (SNOT-22) total score at six weeks. This is more than double the minimal clinically significant difference of 8.9 points. About Lyra Therapeutics Founded in 2018, Lyra Therapeutics is a clinical-stage firm pioneering a novel therapeutic approach for the treatment of debilitating ear, nose, and throat (ENT) diseases that affect millions of people. Its mission is to change the ENT treatment paradigm by giving physicians effective front-line solutions and innovative therapy alternatives for their patients. The company is working on therapeutics for the localized treatment of chronic rhinosinusitis patients (CRS). Lyra has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, which is a common inflammatory disease of the paranasal sinuses that causes debilitating symptoms and significant morbidities. It is headquartered in the Boston region and was created by academic luminaries in the disciplines of chemistry, materials science, and biotechnology, and is supported by top life science investors.

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

Harrow Introduces Next-Gen Compounded Atropine Formulations

Harrow | February 16, 2023

On February 15, 2023, Harrow, a renowned pharmaceutical firm specializing in eyecare in the United States, announced the launch of its next-generation, patent-pending compounded Atropine formulations. These formulations are now accessible through ImprimisRx, a mail-order pharmacy subsidiary wholly owned by Harrow. The following are the key features of ImprimisRx's next-generation Atropine formulations Thoroughly validated analytical tests are conducted to ensure potency, consistency, and stability. The formulations are free of preservatives and boric acid. They possess a physiologic pH of 5.5. They can be stored at room temperature for up to 180 days. Eyecare professionals can purchase these compounded Atropine formulations for as less as $39 per 5mL bottle through various channels, such as online via atropine.com or by contacting ImprimisRx Customer Service at 615-437-4690 via call or text. Compounded formulations are recommended for patients with clinical requirements that are not met by FDA-approved medications. It is essential to note that compounded medications are not reviewed by FDA for their safety and effectiveness. ImprimisRx does not manufacture copies of products that are already available in the market. Harrow's Chairman and Chief Executive Officer, Mark L. Baum, commented, "Our mission has always been to help our eyecare professionals address their patients' unmet needs and to make ophthalmic medications both accessible and affordable. The availability of these innovative compounded atropine formulations is in keeping with our mission. We believe ophthalmologists, optometrists, and the millions of Americans who may benefit from topical atropine therapy, will appreciate the tremendous value these patent-pending formulations offer." (Source – Business Wire) About Harrow Founded in 2012, Harrow is a leading ophthalmic pharmaceutical firm in the United States focused on discovering, developing, and introducing accessible, innovative, and affordable prescription therapies. It holds commercial rights for ten FDA-approved eyecare pharmaceutical products. In addition, the company also operates ImprimisRx, a leading U.S. compounding business that specializes in ophthalmic medications and is licensed to ship prescription drugs in all 50 states. The success of its efforts is reflected in its remarkable financial performance, with a 72% compound annual growth rate achieved during our first eight years in operation. This phenomenal growth rate has established Harrow as one of the fastest-growing ophthalmic pharmaceutical companies in the United States.

Read More

BUSINESS INSIGHTS, PHARMA TECH

Cambrex Announces the Acquisition of Snapdragon Chemistry

Cambrex | January 24, 2023

Cambrex, a renowned global contract development and manufacturing organization (CDMO) offering drug substance, product, and analytical services throughout the drug lifecycle, recently announced the completion of its acquisition of Snapdragon Chemistry, a US-based provider of chemical process development services to a diverse range of emerging and established biopharma customers. Snapdragon Chemistry specializes in the development of active pharmaceutical ingredient (API) batch and continuous flow processes, employing cutting-edge automated technology and proprietary equipment to address complicated process and analytical development challenges. With its headquarters for R&D and manufacturing in Waltham, Massachusetts, Snapdragon's 70+ employees, including 31 Ph.D. scientists, have strong ties to the local scientific community. Cambrex's CEO Tom Loewald commented, "Today, we welcome our new colleagues from Snapdragon to Cambrex." He added, "With Snapdragon's depth of scientific expertise in API process development, I'm certain our customers will see the benefits of this combination and be delighted to work with Snapdragon's team." (Source – PR Newswire) Cambrex's portfolio of specialized pharmaceutical development and manufacturing solutions continues to grow, with Snapdragon reinforcing its experience in continuous flow production in addition to augmenting the recent investments in continuous flow process development capabilities at its North Carolina facility in High Point. Snapdragon's CEO Matt Bio said, "I am extremely proud of what our team at Snapdragon has built over the years." He further added, "With Cambrex, we have found an ideal home for our customers and employees, and I look forward to continued success as part of Cambrex." (Source – PR Newswire) About Cambrex Founded in 1981, Cambrex is a contract development and manufacturing organization (CDMO) that offers drug substances, products, and analytical services throughout the drug lifecycle. It provides a variety of specialized medicinal substance technologies and capabilities, such as controlled substances, biocatalysis, continuous flow, material characterization, solid-state science, stability storage and testing, and potent APIs. Cambrex is a trusted partner in the branded and generic markets for the development and manufacturing of API and finished dosage forms. With over 40 years of experience, it has a growing workforce of over 2,300 specialists serving global clients from North America and Europe.

Read More